Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Human Reproduction (Oxford, England)|June 2, 2001
A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cyclesH J Out, I David, R Ron-El, et al.
Journal of Skin Cancer|December 20, 2012
Genome-wide analysis of gene and protein expression of dysplastic naevus cellsLinda Gao, Frans A van Nieuwpoort, Jacoba J Out-Luiting, et al.
The Journal of Investigative Dermatology|June 22, 2012
NOTCH1 signaling as a therapeutic target in Sézary syndromeLeslie van der Fits, Yongjun Qin, Jacoba J Out-Luiting, et al.
Haematologica|April 1, 2021
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphomaArmando N Bastidas Torres, Davy Cats, Jacoba J Out-Luiting, et al.
Human Reproduction (Oxford, England)|April 30, 1999
A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulationH J Out, S Lindenberg, A L Mikkelsen, et al.
Oncotarget|September 18, 2015
EPHA4 is overexpressed but not functionally active in Sézary syndromeLiesbeth Hameetman, Leslie van der Fits, Willem H Zoutman, et al.
The Journal of Investigative Dermatology|November 19, 2010
MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndromeLeslie van der Fits, Marloes S van Kester, Yongjun Qin, et al.
Human Reproduction (Oxford, England)|December 28, 1999
Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulationH J Out, D D Braat, B M Lintsen, et al.
British Journal of Cancer|November 13, 2003
Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma developmentW Zuidervaart, P A van der Velden, M H Hurks, et al.
Experimental Dermatology|August 18, 2012
A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) miceLeslie van der Fits, Heggert G Rebel, Jacoba J Out-Luiting, et al.
Pageof 9